Open-label placebos reduce weight in obesity: a randomized controlled trial

被引:2
作者
Schaefer, Michael [1 ]
Kuehnel, Anja [1 ]
Enge, Soren [1 ]
机构
[1] MSB Med Sch Berlin, Rudesheimer Str 50, D-14197 Berlin, Germany
关键词
Obesity; Overweight; Placebo; Open-label placebo; Eating behavior; 3-FACTOR EATING-QUESTIONNAIRE; GHRELIN CONCENTRATIONS; DIETARY RESTRAINT; EXERCISE; DISINHIBITION; MIND;
D O I
10.1038/s41598-024-69866-7
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Obesity is a major public health problem worldwide. Different approaches are known to face this problem, for example, dieting, surgery, or drug interventions. It has also been shown that placebos may help to reduce weight and hunger feelings, but the use of placebos is linked to problems with respect to the patient-healthcare-provider relationship. However, recent studies demonstrated that even placebos without deception (open-label placebos) affect symptoms such as pain, anxiety, or emotional distress. Here we aimed to examine whether an open-label placebo may help to lose weight in obesity. Our study included fifty-seven overweight and obese patients who aimed to lose weight using a combination of diet and sports. Patients were randomly divided into two groups. Participants in the open-label placebo group received two placebos each day. A treatment-as-usual group received no pills. Primary outcome included changes of body weight. Secondary outcomes were change of eating behavior and self-management abilities. After 4 weeks we found that participants in the open-label placebo condition lost more weight than the treatment-as-usual group. Furthermore, OLP treatment affected eating behavior. No effects for self-management abilities were found. Although further research is necessary, open-label placebos might help individuals to lose weight.
引用
收藏
页数:8
相关论文
共 54 条
[1]  
Apovian CM, 2016, AM J MANAG CARE, V22
[2]   Deceptive but not open label placebos attenuate motion-induced nausea [J].
Barnes, K. ;
Yu , A. ;
Josupeit, J. ;
Colagiuri, B. .
JOURNAL OF PSYCHOSOMATIC RESEARCH, 2019, 125
[3]   Regulation of food intake by gastrointestinal hormones [J].
Baynes, Kevin C. R. ;
Dhillo, Waljit S. ;
Bloom, Stephen R. .
CURRENT OPINION IN GASTROENTEROLOGY, 2006, 22 (06) :626-631
[4]   Effectiveness of Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder: A Randomized Clinical Trial [J].
Belcher, Annabelle M. ;
Cole, Thomas O. ;
Massey, Ebonie ;
Billing, Amy S. ;
Wagner, Michael ;
Wooten, William ;
Epstein, David H. ;
Hoag, Stephen W. ;
Wickwire, Emerson M. ;
Greenblatt, Aaron D. ;
Colloca, Luana ;
Rotrosen, John ;
Magder, Lawrence ;
Weintraub, Eric ;
Wish, Eric D. ;
Kaptchuk, Ted J. .
JAMA NETWORK OPEN, 2023, 6 (04) :E237099
[5]   Hypothalamic inflammation in metabolic disorders and aging [J].
Bhusal, Anup ;
Rahman, Md Habibur ;
Suk, Kyoungho .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2022, 79 (01)
[6]   Informed consent and clinical trials: where is the placebo effect? [J].
Blease, C. R. ;
Bishop, F. L. ;
Kaptchuk, T. J. .
BMJ-BRITISH MEDICAL JOURNAL, 2017, 356
[7]   Are open-Label Placebos Ethical? Informed Consent and Ethical Equivocations [J].
Blease, Charlotte ;
Colloca, Luana ;
Kaptchuk, Ted J. .
BIOETHICS, 2016, 30 (06) :407-414
[8]   The measurement of dietary restraint, disinhibition and hunger: an examination of the factor structure of the Three Factor Eating Questionnaire (TFEQ) [J].
Bond, MJ ;
McDowell, AJ ;
Wilkinson, JY .
INTERNATIONAL JOURNAL OF OBESITY, 2001, 25 (06) :900-906
[9]   Evidence-based weight loss interventions: Individualized treatment options to maximize patient outcomes [J].
Bray, George A. ;
Ryan, Donna H. .
DIABETES OBESITY & METABOLISM, 2021, 23 :50-62
[10]   Management of obesity [J].
Bray, George A. ;
Fruhbeck, Gema ;
Ryan, Donna H. ;
Wilding, John P. H. .
LANCET, 2016, 387 (10031) :1947-1956